Table 3

Clinical antitumor activity

Overall
(n=27)
Cohort A
(n=6)
Cohort B
(n=21)
Confirmed objective response15 (55.6)2 (33.3)13 (61.9)
Best overall response
 Complete response5 (18.6)1 (16.7)4 (19.0)
 Partial response10 (37)1 (16.7)9 (42.9)
 Stable disease10 (37)3 (50.0)7 (33.3)
 Progressive disease2 (7.4)1 (16.7)1 (4.8)
Disease control25 (92.6)5 (83.3)20 (95.2)
  • Data are n (%), unless otherwise specified.

  • Responses were assessed in accordance with the Response Evaluation Criteria in Solid Tumors version 1.1.